The Washington Post | December 7, 2022
“The writing’s been on the wall for many months, probably half a year, that Gavi was going to wind down Covax,” said Lawrence Gostin, a global health law expert at Georgetown University.
Two main factors appear to be at play, he said: plummeting demand for coronavirus vaccinations in low-income countries and “a broad, growing, global belief that the emergency phase of covid is nearing its end.”